GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (OTCPK:SRNE) » Definitions » Beneish M-Score

Sorrento Therapeutics (Sorrento Therapeutics) Beneish M-Score : -3.37 (As of Apr. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sorrento Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.37 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sorrento Therapeutics's Beneish M-Score or its related term are showing as below:

SRNE' s Beneish M-Score Range Over the Past 10 Years
Min: -3.43   Med: -1.17   Max: 102.59
Current: -3.37

During the past 13 years, the highest Beneish M-Score of Sorrento Therapeutics was 102.59. The lowest was -3.43. And the median was -1.17.


Sorrento Therapeutics Beneish M-Score Historical Data

The historical data trend for Sorrento Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Beneish M-Score Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 -0.76 -2.77 -2.79 -3.23

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.81 -2.65 -3.23 -3.43 -3.37

Competitive Comparison of Sorrento Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Sorrento Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Beneish M-Score falls into.



Sorrento Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sorrento Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1328+0.528 * 1.5099+0.404 * 0.9766+0.892 * 1.1689+0.115 * 0.7913
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8464+4.679 * -0.26921-0.327 * 1.5011
=-3.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $32.73 Mil.
Revenue was 15.025 + 16.251 + 15.594 + 17.4 = $64.27 Mil.
Gross Profit was 6.572 + 11.065 + 1.872 + 9.132 = $28.64 Mil.
Total Current Assets was $133.11 Mil.
Total Assets was $456.69 Mil.
Property, Plant and Equipment(Net PPE) was $106.65 Mil.
Depreciation, Depletion and Amortization(DDA) was $13.93 Mil.
Selling, General, & Admin. Expense(SGA) was $193.54 Mil.
Total Current Liabilities was $264.95 Mil.
Long-Term Debt & Capital Lease Obligation was $74.19 Mil.
Net Income was -95.212 + -139.616 + -223.692 + -89.576 = $-548.10 Mil.
Non Operating Income was -28.43 + -52.811 + -128.515 + 19.233 = $-190.52 Mil.
Cash Flow from Operations was -55.659 + -49.459 + -68.338 + -61.171 = $-234.63 Mil.
Total Receivables was $24.72 Mil.
Revenue was 11.461 + 18.385 + 13.076 + 12.062 = $54.98 Mil.
Gross Profit was 5.757 + 12.627 + 9.939 + 8.675 = $37.00 Mil.
Total Current Assets was $196.05 Mil.
Total Assets was $632.13 Mil.
Property, Plant and Equipment(Net PPE) was $128.62 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.94 Mil.
Selling, General, & Admin. Expense(SGA) was $195.63 Mil.
Total Current Liabilities was $145.32 Mil.
Long-Term Debt & Capital Lease Obligation was $167.39 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(32.725 / 64.27) / (24.715 / 54.984)
=0.50918 / 0.449494
=1.1328

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(36.998 / 54.984) / (28.641 / 64.27)
=0.672887 / 0.445636
=1.5099

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (133.111 + 106.645) / 456.692) / (1 - (196.048 + 128.624) / 632.132)
=0.475016 / 0.486386
=0.9766

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=64.27 / 54.984
=1.1689

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.94 / (12.94 + 128.624)) / (13.927 / (13.927 + 106.645))
=0.091407 / 0.115508
=0.7913

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(193.544 / 64.27) / (195.632 / 54.984)
=3.011421 / 3.557981
=0.8464

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((74.187 + 264.949) / 456.692) / ((167.385 + 145.321) / 632.132)
=0.742592 / 0.494685
=1.5011

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-548.096 - -190.523 - -234.627) / 456.692
=-0.26921

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sorrento Therapeutics has a M-score of -3.37 suggests that the company is unlikely to be a manipulator.


Sorrento Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (Sorrento Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Executives
Henry Ji director, officer: See Remarks 5370 RUETTE DE MER, SAN DIEGO CA 92130
Tammy Reilly director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Kim Janda director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Najjam Asghar officer: Chief Financial Officer C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Edgar Lee director C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071
Jerome B Zeldis officer: See Remarks 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Jaisim Shah director C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Abg Management Ltd 10 percent owner UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000
Jiong Shao officer: Chief Financial Officer SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000
George K Ng officer: See Remarks C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121

Sorrento Therapeutics (Sorrento Therapeutics) Headlines

From GuruFocus